Stefan Fraenkel takes over as chief of Inceptua Group; Christi Shaw has a plan to make Yescarta safer
→ After its subsidiary Inceptua Medicines Access inked a deal with Onconova Therapeutics to make available intravenous rigosertib via a pre-approval access program in selected countries across the world, Inceptua Group has tapped Stefan Fraenkel to head the company’s operations as CEO. Fraenkel, currently EVP of the company’s business unit Inceptua Pharma, will succeed Alan Raffensperger — who is moving to the position of executive vice-chairman of the group. Fraenkel joined the company in 2017 and holds experience from his previous roles at Wyeth Pharmaceuticals and Sobi.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.